The DOI matches its Crossref record.
THE TREATMENT OF DEPRESSIVE STATES WITH G 22355 (IMIPRAMINE HYDROCHLORIDE)
Abstract
Over a three-year period, more than 500 psychiatric patients of various diagnostic categories were treated with imipramine hydrochloride. It was demonstrated that the compound has potent antidepressant action. Best responses were obtained in cases of endogenous depression showing the typical symptoms of mental and motor retardation, fatigue, feeling of heaviness, hopelessness, guilt, and despair. The condition is furthermore characterized by the aggravation of symptoms in the morning with a tendency to improvement during the day. Treatment with imipramine hydrochloride resulted in full or social recovery in a high percentage of the patients. As a rule, the initial response was evident within 2 to 3 days, while in some cases 1 to 4 weeks of therapy were required. In view of the symptomatic nature of the action of imipramine hydrochloride, therapy must be maintained as long as the illness lasts. The side effects noted were relatively slight, and with the exception of one case of severe allergic exanthema necessitating discontinuance of treatment, no serious complications were encountered. In some cases of depression, particularly those associated with organic brain damage or schizophrenic psychosis, transitory states of agitation or exacerbation of the psychotic features were noted. These observations suggest the importance of a proper selection of the patients as to type and etiology of depression. While in a number of instances, neurotic, schizophrenic or other depressions were also benefited by the drug, particularly when used in combination with chlorpromazine, electroshock or psychotherapy, it is concluded that imipramine hydrochloride is primarily indicated and effective in the treatment of endogenous depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Schildkraut, J. J., & Kety, S. S. (1967) · Science · doi:10.1126/science.156.3771.21 · Cited by 875
SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
X-ray structure of dopamine transporter elucidates antidepressant mechanism
Penmatsa, A., Wang, K. H., & Gouaux, E. (2013) · Nature · doi:10.1038/nature12533 · Cited by 612
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Fava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
Central monoamines and their role in major depression
Elhwuegi, A. S. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.11.018 · Cited by 504
Lopez-Munoz, F., & Alamo, C. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168001 · Cited by 476
Hyperforin as a possible antidepressant component of hypericum extracts
Chatterjee, S. S., Bhattacharya, S. K., Wonnemann, M., Singer, A., & Müller, W. E. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00299-9 · Cited by 443
Stuck in a rut: rethinking depression and its treatment
Holtzheimer, P. E., & Mayberg, H. S. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2010.10.004 · Cited by 430
Taylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1217 · Cited by 406
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Prediction of Tricyclic Antidepressant Response: A Critical Review
Bielski, R. J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770120083009 · Cited by 349
Deep Brain Stimulation for Psychiatric Disorders
Holtzheimer, P. E., & Mayberg, H. S. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113638 · Cited by 329
Efficacy of antidepressants in adults
Moncrieff, J., & Kirsch, I. (2005) · BMJ · doi:10.1136/bmj.331.7509.155 · Cited by 327
Role of norepinephrine in the pathophysiology and treatment of mood disorders
Ressler, K. J., & Nemeroff, C. B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00127-4 · Cited by 307
Raskin, A. (1970) · Archives of General Psychiatry · doi:10.1001/archpsyc.1970.01750020068009 · Cited by 301
Genetics Factors in Major Depression Disease
Shadrina, M., Bondarenko, E. A., & Slominsky, P. A. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00334 · Cited by 288
Akiskal, H. S. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770300098011 · Cited by 282
Blier, P. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00036-6 · Cited by 282
Pharmacology of Antidepressants
Frazer, A. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199704001-00002 · Cited by 269
Pharmacology of Antidepressants—Characteristics of the Ideal Drug
RICHELSON, E. (1994) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61375-5 · Cited by 257
Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300341 · Cited by 252
From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder
Liu, B., Liu, J., Wang, M., Zhang, Y., & Li, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00305 · Cited by 249
Cytokines as biomarkers in depressive disorder: current standing and prospects
Lichtblau, N., Schmidt, F. M., Schumann, R., Kirkby, K. C., & Himmerich, H. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.813442 · Cited by 155
Illness risk following rapid versus gradual discontinuation of antidepressants
Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09060880 · Cited by 123
Braslow, J. T., & Marder, S. R. (2019) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050718-095514 · Cited by 122
Psychopharmacological advances in eating disorders
Himmerich, H., & Treasure, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1383895 · Cited by 119
Standardisation framework for the Maudsley staging method for treatment resistance in depression
Fekadu, A., Donocik, J. G., & Cleare, A. J. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1679-x · Cited by 106
“Soon after the introduction of imipramine [8], Robert Kuhn conceded that “in many cases, however, there is merely some degree of improvement, making the condition more bearable for the patient, and even permitting * Correspondence: abebaw.”
BackgroundKetamine and the Future of Rapid-Acting Antidepressants
Riggs, L. M., & Gould, T. D. (2021) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-072120-014126 · Cited by 87
Hieronymus, F., Lisinski, A., Nilsson, S., & Eriksson, E. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30216-0 · Cited by 73
Phosphorylation of MeCP2 at Ser421 Contributes to Chronic Antidepressant Action
Hutchinson, A. N., Deng, J. V., Cohen, S., & West, A. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2156-12.2012 · Cited by 53
Long-Term Impact of Residual Symptoms in Treatment-Resistant Depression
Fekadu, A., Wooderson, S. C., Rane, L. J., Markopoulou, K., Poon, L., & Cleare, A. J. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600906 · Cited by 23
Wierońska, J. M., & Pilc, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.010 · Cited by 23
Metadata
- Authors
- KUHN, R.
- Venue
- American Journal of Psychiatry
- Published
- 1958-11
- Volume
- 115
- Issue
- 5
- Pages
- 459-464
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2093036934
- Cited by
- 615
- References
- 0
- FWCI
- 22.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.